# A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

> **NCT04959305** · PHASE2 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 245 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** HCP1803-3
- **DRUG:** RLD2003
- **DRUG:** RLD2004
- **DRUG:** RLD2005
- **DRUG:** HPP2003-3
- **DRUG:** HPP2005

## Key facts

- **NCT ID:** NCT04959305
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-22
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04959305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04959305, "A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04959305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*